Oric Pharmaceuticals (ORIC) Other Non-Current Assets (2019 - 2026)
Oric Pharmaceuticals' (ORIC) quarterly Other Non-Current Assets came in at $6.6 million in Q1 2026, down 21.06% YoY from $8.4 million in Q1 2025, and down 8.89% on a QoQ basis from $7.2 million in Q4 2025.
Oric Pharmaceuticals (ORIC) Other Non-Current Assets (2019 - 2026) Analysis & Trends
Oric Pharmaceuticals (ORIC) has 8 years of Other Non-Current Assets data on file, last reported at $6.6 million in Q1 2026.
- Quarterly Other Non-Current Assets fell 21.06% year-over-year to $6.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.6 million (down 21.06% YoY) and the FY2025 annual result came in at $7.2 million, down 19.19% from the prior year.
- Other Non-Current Assets retreated to $6.6 million in Q1 2026, from $7.2 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $12.4 million in Q2 2022 to a low of $6.6 million in Q1 2026.
- A 5-year average of $9.6 million and a median of $9.6 million in 2024 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets jumped 755.63% — and 2025, when it retreated 25.35%.
- Tracing ORIC's Other Non-Current Assets over 5 years: stood at $11.5 million in 2022, then declined by 15.81% to $9.7 million in 2023, then decreased by 7.51% to $9.0 million in 2024, then dropped by 19.19% to $7.2 million in 2025, then fell by 8.89% to $6.6 million in 2026.
- The last three Other Non-Current Assets figures came in at $6.6 million (Q1 2026), $7.2 million (Q4 2025), and $7.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Oric Pharmaceuticals | 1.44 Bn | 1.44 Bn | - | 5.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.95 Mn |
| Mar 31, 2026 | 6.60 Mn |
| Dec 31, 2025 | 7.25 Mn |
| Sep 30, 2025 | 7.13 Mn |
| Jun 30, 2025 | 7.76 Mn |
| Mar 31, 2025 | 8.37 Mn |
| Dec 31, 2024 | 8.97 Mn |
| Sep 30, 2024 | 9.55 Mn |
| Jun 30, 2024 | 9.30 Mn |
| Mar 31, 2024 | 9.21 Mn |
| Dec 31, 2023 | 9.70 Mn |
| Sep 30, 2023 | 10.17 Mn |
| Jun 30, 2023 | 10.63 Mn |
| Mar 31, 2023 | 11.06 Mn |
| Dec 31, 2022 | 11.52 Mn |
| Sep 30, 2022 | 11.95 Mn |
| Jun 30, 2022 | 12.38 Mn |
| Mar 31, 2022 | 11.94 Mn |
| Dec 31, 2021 | 12.32 Mn |
| Sep 30, 2021 | 12.55 Mn |